Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serious Asthma Outcomes and Asthma Exacerbations with Maintenance on Inhaled Corticosteroid (Mometasone Furoate)/Long-Acting Beta Agonist (Formoterol) Combination Compared to Step Down to Mometasone Monotherapy.
Weinstein CLJ, Ryan N, Zhang X, Shekar T, Gates D, Lane SJ, Agache I, Nathan RA; SPIRO Investigators. Weinstein CLJ, et al. J Allergy Clin Immunol Pract. 2020 May;8(5):1634-1644.e1. doi: 10.1016/j.jaip.2020.01.021. Epub 2020 Jan 23. J Allergy Clin Immunol Pract. 2020. PMID: 31981733 Clinical Trial.
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
Weinstein C, Jordan K, Green S, Khanani S, Beckford-Brathwaite E, Vallejos W, Pong A, Noga SJ, Rapoport BL. Weinstein C, et al. BMC Cancer. 2020 Sep 25;20(1):918. doi: 10.1186/s12885-020-07259-5. BMC Cancer. 2020. PMID: 32988373 Free PMC article. Clinical Trial.
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.
Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, Vallejos W, Liang LW, Noga SJ, Rapoport BL. Weinstein C, et al. Ann Oncol. 2016 Jan;27(1):172-8. doi: 10.1093/annonc/mdv482. Epub 2015 Oct 8. Ann Oncol. 2016. PMID: 26449391 Free PMC article. Clinical Trial.
Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, Pong A, Noga SJ, Rapoport BL. Weinstein C, et al. Support Care Cancer. 2018 Nov;26(11):3773-3780. doi: 10.1007/s00520-018-4242-x. Epub 2018 May 28. Support Care Cancer. 2018. PMID: 29808377 Clinical Trial.
Intraoperative Surprise: A Rare Hernia Variant Uncovered.
Weinstein C, Kirsch A. Weinstein C, et al. Urology. 2024 Oct 9:S0090-4295(24)00874-4. doi: 10.1016/j.urology.2024.10.017. Online ahead of print. Urology. 2024. PMID: 39389369 No abstract available.
158 results